Review article · 2025 · Open access
T cell engagers emerge as a compelling therapeutic modality
The Journal of Experimental Medicine, 223(2) · Published 3 December 2025 · DOI 10.1084/jem.20251652
In brief
“T cell engagers emerge as a compelling therapeutic modality” is a 2025 review article by Patrick A. Baeuerle and 3 co-authors, published in The Journal of Experimental Medicine. OpenAlex counts 27 citations as of 16 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access: the full text is free to read at The Journal of Experimental Medicine.
- Citations
- 27
- Most cited in
- 2026 (27)
- Field-weighted impact
- 1.94
- References
- 125
- Authors
- 4
Abstract
T cell engagers (TCEs) are antibody-based constructs designed to transiently reprogram cytotoxic T lymphocytes for target cell elimination by simultaneously binding the T cell receptor and a specific surface antigen on the target cell. Over the past 12 years, 10 TCEs were approved by the US Food and Drug Administration, and an additional two by the European Medicines Agency. Nine TCEs treat hematologic malignancies, and three target solid tumors. Over 150 TCEs are being investigated in clinical trials, recently also in autoimmune diseases. Here, we discuss the learnings from the 12 approved TCEs. A surprising variety of molecular designs and biochemical characteristics appear suitable for approval. On the clinical side, we review targets, indications, dosing, schedules, side effects, mitigation strategies for adverse events, and efficacy. High flexibility in design and choice of target, scalability, high response rates as a monotherapy in hematologic malignancies, and emerging efficacy against solid tumors and in autoimmune diseases make TCEs an attractive therapeutic modality.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Baeuerle, P. A., Sauer, K., Grieshaber‐Bouyer, R., & Michaelson, J. S. (2025). T cell engagers emerge as a compelling therapeutic modality. The Journal of Experimental Medicine, 223(2). https://doi.org/10.1084/jem.20251652
MLA 9
Baeuerle, Patrick A., et al. “T cell engagers emerge as a compelling therapeutic modality.” The Journal of Experimental Medicine, vol. 223, no. 2, 2025. https://doi.org/10.1084/jem.20251652.
Chicago
Baeuerle, Patrick A., Karsten Sauer, Ricardo Grieshaber‐Bouyer, and Jennifer S. Michaelson. 2025. “T cell engagers emerge as a compelling therapeutic modality.” The Journal of Experimental Medicine 223 (2). https://doi.org/10.1084/jem.20251652.
Harvard
Baeuerle, P. A. et al. (2025) ‘T cell engagers emerge as a compelling therapeutic modality’, The Journal of Experimental Medicine, 223(2). doi:10.1084/jem.20251652.
IEEE
P. A. Baeuerle, K. Sauer, R. Grieshaber‐Bouyer, and J. S. Michaelson, “T cell engagers emerge as a compelling therapeutic modality,” The Journal of Experimental Medicine, vol. 223, no. 2, 2025, doi: 10.1084/jem.20251652.
BibTeX
@article{baeuerle2025cell,
title = {{T cell engagers emerge as a compelling therapeutic modality}},
author = {Baeuerle, Patrick A. and Sauer, Karsten and Grieshaber‐Bouyer, Ricardo and Michaelson, Jennifer S.},
journal = {The Journal of Experimental Medicine},
year = {2025},
volume = {223},
number = {2},
doi = {10.1084/jem.20251652},
url = {https://doi.org/10.1084/jem.20251652}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- T-cell engagers
- bispecific antibodies
- T cell receptor engagement
- cytotoxic T lymphocytes
- hematologic malignancies
- solid tumors
- autoimmune disease
- antibody design
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Baeuerle, P. A., Sauer, K., Grieshaber‐Bouyer, R., & Michaelson, J. S. (2025). T cell engagers emerge as a compelling therapeutic modality. The Journal of Experimental Medicine, 223(2). https://doi.org/10.1084/jem.20251652
How many times has this paper been cited?
27 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Journal of Experimental Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Patrick A. Baeuerle, Karsten Sauer, Ricardo Grieshaber‐Bouyer, Jennifer S. Michaelson.
What is the DOI of this paper?
10.1084/jem.20251652, permanently at https://doi.org/10.1084/jem.20251652. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.